Dry Age-Related Macular Degeneration Market—Forecast till 2027
出 版 商：Market Research Future
出版日期：2021/08/01
頁 數：171頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Multi-User License)
USD 6,250 (Multi-User License)
Dry Age-Related Macular Degeneration Market—Forecast till 2027
Dry Age-Related Macular Degeneration AMD Market Forecast
According to market research future analysis, the global dry age-related macular degeneration AMD market is projected to witness a significant CAGR of 8.62% during the review period to surpass USD 6,113.33 million by the end of 2027. Dry macular degeneration is a typical eye issue among individuals aged more than 50. The macula is the piece of the retina answerable for clear vision in your immediate view.
The development of the worldwide dry Age-related Macular Degeneration (AMD) market is ascribed to the developing geriatric populace and expanding pervasiveness old enough related macular degeneration, and the presentation of novel treatment techniques for dry AMD combined with the expanding number of clinical preliminaries zeroed in on dry AMD. Different variables like expanding medical services use are probably going to assist the market with developing. In any case, a large number of bombed clinical preliminaries for dry AMD medications may hamper the market development somewhat. The global market expansion is propelled by the growing geriatric population and rising incidences of dry age-related macular degeneration.
Segment Overview
The global dry age-related macular degeneration AMD market has been divided based on stages, age group, route of administration, diagnosis & treatment, and end-user.
Based on Stages the global market has been classified into Early stage of AMD, Intermediate Stage of AMD, and Late Stage of AMD. By age group segment, the global market is categorized into above 75 years, above 60 years, and above 40 years.
In terms of diagnosis & treatment, the dry age-related macular degeneration AMD market is bifurcated into treatment and diagnosis. The treatment is further classified into nutrition therapy and telescopic lens implant. The nutrition therapy segment is sub-segmented into antioxidants and others. Based on the route of administration, the market is divided into oral and injectables. In terms of end-user, the market is categorized into hospitals &clinics, diagnostic centers, academic &research institutes, and others.
Regional Analysis
Based on region, the global dry AMD market has been classified into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is likely to drive the largest market for global dry AMD owing to the government initiatives and funding in the region. Europe holds the second biggest portion of the overall industry because of the expanding more seasoned populace and rising patient populace. Furthermore, further developing government drives, expanding medical care casings, and rising interest for mechanically inventive therapy are driving the development of the dry age-related macular degeneration market in Europe. The Asia-Pacific exhibits the rapidly developing business sector for age-related macular degeneration as it is creating at an exceptionally fast speed and has shown the rise of numerous players.
Major Players
Major players of the global dry age-related macular degeneration AMD market are Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), and Stealth Biotherapeutics Inc. (US)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Dry Age-Related Macular Degeneration AMD Market Forecast
According to market research future analysis, the global dry age-related macular degeneration AMD market is projected to witness a significant CAGR of 8.62% during the review period to surpass USD 6,113.33 million by the end of 2027. Dry macular degeneration is a typical eye issue among individuals aged more than 50. The macula is the piece of the retina answerable for clear vision in your immediate view.
The development of the worldwide dry Age-related Macular Degeneration (AMD) market is ascribed to the developing geriatric populace and expanding pervasiveness old enough related macular degeneration, and the presentation of novel treatment techniques for dry AMD combined with the expanding number of clinical preliminaries zeroed in on dry AMD. Different variables like expanding medical services use are probably going to assist the market with developing. In any case, a large number of bombed clinical preliminaries for dry AMD medications may hamper the market development somewhat. The global market expansion is propelled by the growing geriatric population and rising incidences of dry age-related macular degeneration.
Segment Overview
The global dry age-related macular degeneration AMD market has been divided based on stages, age group, route of administration, diagnosis & treatment, and end-user.
Based on Stages the global market has been classified into Early stage of AMD, Intermediate Stage of AMD, and Late Stage of AMD. By age group segment, the global market is categorized into above 75 years, above 60 years, and above 40 years.
In terms of diagnosis & treatment, the dry age-related macular degeneration AMD market is bifurcated into treatment and diagnosis. The treatment is further classified into nutrition therapy and telescopic lens implant. The nutrition therapy segment is sub-segmented into antioxidants and others. Based on the route of administration, the market is divided into oral and injectables. In terms of end-user, the market is categorized into hospitals &clinics, diagnostic centers, academic &research institutes, and others.
Regional Analysis
Based on region, the global dry AMD market has been classified into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is likely to drive the largest market for global dry AMD owing to the government initiatives and funding in the region. Europe holds the second biggest portion of the overall industry because of the expanding more seasoned populace and rising patient populace. Furthermore, further developing government drives, expanding medical care casings, and rising interest for mechanically inventive therapy are driving the development of the dry age-related macular degeneration market in Europe. The Asia-Pacific exhibits the rapidly developing business sector for age-related macular degeneration as it is creating at an exceptionally fast speed and has shown the rise of numerous players.
Major Players
Major players of the global dry age-related macular degeneration AMD market are Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), and Stealth Biotherapeutics Inc. (US)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION
4.2.2 INCREASING HEALTHCARE EXPENDITURE
4.3 RESTRAINTS
4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD
4.4 OPPORTUNITIES
4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD
4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT
4.5 EPIDEMIOLOGY OF DRY AMD
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON PATIENTS WITH DRY AMD
5.3.3 IMPACT ON CLINICAL TRIALS
5.3.4 IMPACT ON R&D
5.3.5 IMPACT ON MARKET GROWTH
6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES
6.1 OVERVIEW
6.2 EARLY AGE-RELATED MACULAR DEGENERATION
6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
6.4 LATE AGE-RELATED MACULAR DEGENERATION
7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP
7.1 OVERVIEW
7.2 ABOVE 40 YEARS
7.3 ABOVE 60 YEARS
7.4 ABOVE 75 YEARS
8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT
8.1 OVERVIEW
8.2 TREATMENT
8.3 DIAGNOSIS
9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLES
10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITAL & CLINICS
10.3 DIAGNOSTIC CENTERS
10.4 ACADEMIC RESEARCH INSTITUTES
10.5 OTHERS
11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 COMPETITIVEOVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET
12.4 COMPETITIVE BENCHMARKING
12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 CONTRACTS & AGREEMENTS
12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES
12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
12.6.4 INVESTMENT
12.7 MAJOR PLAYERS FINANCIAL MATRIX
12.7.1 SALES, 2020
12.7.2 R&D EXPENDITURE, 2020
13 COMPANY PROFILES
13.1 SANTEN PHARMACEUTICALS INC.
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ALLERGAN PLC
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 ALLERGAN: KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS)
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 ALIMERA SCIENCES INC.
13.4.1 COMPANY OVERVIEWS
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP)
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS/SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD
13.6.1 COMPANY OVERVIEWS
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 BELITE BIO INC.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 KUBOTA VISION INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 IVERIC BIO
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 EYESTEM RESEARCH PVT LTD
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
13.11 YUYANG DNU CO., LTD
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL OVERVIEW
13.11.3 PRODUCTS/SERVICES OFFERED
13.11.4 KEY DEVELOPMENTS
13.11.5 SWOT ANALYSIS
13.11.6 KEY STRATEGIES
13.12 STEALTH BIOTHERAPEUTICS CORP
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL OVERVIEW
13.12.3 PRODUCTS/SERVICES OFFERED
13.12.4 KEY DEVELOPMENTS
13.12.5 SWOT ANALYSIS
13.12.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
?
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION
4.2.2 INCREASING HEALTHCARE EXPENDITURE
4.3 RESTRAINTS
4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD
4.4 OPPORTUNITIES
4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD
4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT
4.5 EPIDEMIOLOGY OF DRY AMD
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON PATIENTS WITH DRY AMD
5.3.3 IMPACT ON CLINICAL TRIALS
5.3.4 IMPACT ON R&D
5.3.5 IMPACT ON MARKET GROWTH
6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES
6.1 OVERVIEW
6.2 EARLY AGE-RELATED MACULAR DEGENERATION
6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
6.4 LATE AGE-RELATED MACULAR DEGENERATION
7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP
7.1 OVERVIEW
7.2 ABOVE 40 YEARS
7.3 ABOVE 60 YEARS
7.4 ABOVE 75 YEARS
8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT
8.1 OVERVIEW
8.2 TREATMENT
8.3 DIAGNOSIS
9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLES
10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITAL & CLINICS
10.3 DIAGNOSTIC CENTERS
10.4 ACADEMIC RESEARCH INSTITUTES
10.5 OTHERS
11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 COMPETITIVEOVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET
12.4 COMPETITIVE BENCHMARKING
12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 CONTRACTS & AGREEMENTS
12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES
12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
12.6.4 INVESTMENT
12.7 MAJOR PLAYERS FINANCIAL MATRIX
12.7.1 SALES, 2020
12.7.2 R&D EXPENDITURE, 2020
13 COMPANY PROFILES
13.1 SANTEN PHARMACEUTICALS INC.
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ALLERGAN PLC
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 ALLERGAN: KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS)
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 ALIMERA SCIENCES INC.
13.4.1 COMPANY OVERVIEWS
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP)
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS/SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD
13.6.1 COMPANY OVERVIEWS
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 BELITE BIO INC.
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 KUBOTA VISION INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 IVERIC BIO
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 EYESTEM RESEARCH PVT LTD
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
13.11 YUYANG DNU CO., LTD
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL OVERVIEW
13.11.3 PRODUCTS/SERVICES OFFERED
13.11.4 KEY DEVELOPMENTS
13.11.5 SWOT ANALYSIS
13.11.6 KEY STRATEGIES
13.12 STEALTH BIOTHERAPEUTICS CORP
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL OVERVIEW
13.12.3 PRODUCTS/SERVICES OFFERED
13.12.4 KEY DEVELOPMENTS
13.12.5 SWOT ANALYSIS
13.12.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
?
